Hair loss seasonal shedding is a well-recognised phenomenon that causes many people to notice more hair on their pillow, in the shower drain, or on their hairbrush during autumn and, to a lesser extent, spring. This temporary increase in hair fall is a normal variation of the hair growth cycle, known as telogen effluvium, and typically resolves on its own within a few months. Understanding what drives seasonal shedding, how to distinguish it from other forms of hair loss, and when to seek medical advice can help reduce unnecessary anxiety and ensure that any underlying conditions are identified and treated promptly.

What Is Seasonal Hair Shedding and Is It Normal?

Seasonal hair shedding is a normal, temporary increase in hair fall caused by a larger cohort of follicles entering the telogen (resting) phase simultaneously; because follicles remain intact, hair typically regrows without treatment.

Seasonal hair shedding is a recognised, physiological pattern in which a person notices a temporary increase in the amount of hair falling out during certain periods of the year, most commonly in autumn (September to November) and, to a lesser extent, in spring. It is not classified as a separate medical disorder; rather, it represents a seasonal pattern of telogen effluvium — a descriptive term for a temporary shift in the hair growth cycle — and is considered a normal variation for many people. Most people lose between 50 and 100 hairs per day under normal circumstances; during a seasonal shedding episode, this figure may temporarily rise, leading to more hair on the pillow, in the shower drain, or on a hairbrush.

The underlying process involves a shift in the proportion of hair follicles entering the resting (telogen) phase of the growth cycle simultaneously. When a larger-than-usual cohort of follicles enters telogen at the same time, the subsequent shedding phase produces a noticeable increase in hair loss roughly two to three months later. Importantly, because the follicles themselves remain intact and healthy, the hair typically regrows without intervention.

Not sure if this is normal? Chat with one of our pharmacists →

Seasonal shedding affects both men and women, though it may be more noticeable in individuals with longer hair simply because shed strands are more visible. The NHS notes that temporary hair loss (telogen effluvium) is common and, in the absence of other symptoms, is generally not a cause for concern. Understanding this distinction is the first step towards managing anxiety around hair loss appropriately.

Why Hair Loss Increases at Certain Times of Year

Shortening daylight hours in late summer and autumn are thought to trigger a simultaneous shift of follicles into the resting phase, though the precise mechanism in humans remains unproven.

The precise biological mechanisms driving seasonal hair shedding in humans are not yet fully established, and the following explanations should be understood as current hypotheses rather than proven causes.

One leading hypothesis is that the hair follicle cycle is influenced by photoperiod — the number of daylight hours — in a manner similar to that observed in other mammals. As daylight hours shorten in late summer and early autumn, changes in melatonin and prolactin secretion may signal a larger proportion of follicles to enter the telogen phase simultaneously; however, direct evidence for this mechanism in humans remains limited. Trichogram studies published in dermatological literature (including data from the British Journal of Dermatology) have reported higher proportions of telogen hairs in late summer and early autumn, lending some support to a seasonal pattern, though findings vary across populations. Separately, analyses of internet search data have found consistent autumn peaks in hair-loss-related queries across multiple countries, providing epidemiological corroboration, albeit with the inherent limitations of such data.

Ultraviolet (UV) light exposure during summer months is also thought to influence scalp physiology; as UV levels drop, the scalp environment may change in ways that contribute to follicle cycling shifts. Again, this remains a plausible hypothesis rather than an established mechanism.

Other factors that may amplify seasonal shedding in susceptible individuals include:

• Nutritional fluctuations: Dietary changes between seasons can affect levels of vitamin D, iron, and zinc — all of which are important for healthy hair growth — though their role as drivers of seasonality specifically has not been proven.

• Physiological stress: The transition between seasons can coincide with increased psychological or physical stress, which independently triggers telogen effluvium.

• Hormonal variation: Fluctuations in oestrogen and thyroid hormones across the year may play a modest role, particularly in women, though evidence is limited.

Whilst there is no single definitive explanation, the convergence of these factors provides a plausible framework for why hair loss seasonal shedding follows a broadly predictable annual pattern in susceptible individuals.

How to Tell Seasonal Shedding Apart From Other Hair Loss

Seasonal shedding presents as diffuse hair fall across the whole scalp without patches, scalp inflammation, or systemic symptoms; patchy loss, progressive thinning, or scalp changes should prompt GP assessment.

Distinguishing seasonal shedding from other forms of hair loss is clinically important, as some causes of hair loss require prompt investigation and treatment. Seasonal shedding typically presents as a diffuse increase in hair fall across the entire scalp, without visible thinning patches, scalp inflammation, or changes to the hair shaft itself. It usually resolves spontaneously within two to four months, and regrowth is evident thereafter.

By contrast, the following features should prompt a consultation with a GP:

• Patchy hair loss: Discrete bald patches may indicate alopecia areata, an autoimmune condition that warrants specialist assessment (NICE CKS: Alopecia areata).

• Progressive thinning at the crown or hairline: This pattern is more consistent with androgenetic alopecia (male- or female-pattern hair loss), which is chronic and unlikely to resolve without treatment (NICE CKS: Male and Female pattern hair loss).

• Scalp symptoms: Redness, scaling, itching, or pustules suggest a dermatological condition such as seborrhoeic dermatitis, tinea capitis (scalp ringworm), or lichen planopilaris. Suspected scarring alopecia — indicated by pain, burning, perifollicular erythema or scale, or tufting — warrants urgent specialist referral, as irreversible follicle damage may occur without prompt treatment.

• Systemic symptoms: Fatigue, weight change, cold intolerance, or irregular periods alongside hair loss may point to an underlying condition such as hypothyroidism, iron deficiency anaemia, or polycystic ovary syndrome (PCOS).

A useful clinical rule of thumb is the pull test: gently grasping a small bunch of approximately 40 hairs and pulling firmly. Extracting more than six hairs suggests active shedding. However, this test should be interpreted alongside the full clinical picture rather than in isolation.

If hair loss persists beyond six months, worsens progressively, or is accompanied by any of the above features, a GP may arrange baseline blood tests based on clinical suspicion. These commonly include full blood count (FBC), serum ferritin, and thyroid function tests (TFTs); vitamin D testing is considered where there is a clinical risk of deficiency, rather than as a routine screen for hair loss. This approach is consistent with NICE CKS and PCDS guidance on the assessment of hair loss in primary care.

Managing Seasonal Hair Shedding at Home

Supportive self-care — including adequate iron and vitamin D intake, gentle hair handling, and stress management — is the mainstay of managing seasonal shedding, as no medical treatment is usually required.

For the majority of people experiencing straightforward seasonal shedding, no medical treatment is required. The most effective approach is supportive self-care aimed at maintaining scalp health and minimising additional stressors on the hair follicle during the shedding period.

Nutritional support is a practical first step. Ensuring adequate intake of key micronutrients known to support hair growth is advisable:

• Iron: Found in red meat, legumes, and leafy greens. Iron deficiency is one of the most common reversible causes of hair loss in women. Iron supplementation should only be taken if deficiency has been confirmed by a blood test and on the advice of a clinician; unsupervised supplementation is not recommended.

• Vitamin D: Synthesis decreases significantly in the UK between October and March. The NHS recommends that all adults consider a daily supplement of 10 micrograms (400 IU) during this period. This advice applies to general health; there is no established evidence that vitamin D supplementation reverses hair loss in those who are not deficient.

• Zinc and biotin: Present in nuts, seeds, eggs, and wholegrains. Severe deficiency of either can impair hair growth, but supplementation beyond dietary needs offers limited additional benefit in those who are not deficient and is not routinely recommended. Importantly, high-dose biotin supplements can interfere with certain laboratory tests, including thyroid function tests and cardiac troponin assays, potentially producing misleading results. If you are taking biotin supplements, inform your clinician before any blood tests; your laboratory may advise pausing supplementation beforehand (MHRA Drug Safety Update: biotin interference with laboratory tests).

Gentle hair care practices can reduce mechanical stress on already-shedding hair:

• Avoid tight hairstyles such as high ponytails or braids during peak shedding periods.

• Use a wide-toothed comb on wet hair rather than a fine-toothed brush.

• Minimise heat styling and chemical treatments where possible.

• Choose a mild, sulphate-free shampoo suited to your scalp type.

Stress management is also relevant, as psychological stress is a well-established trigger for telogen effluvium. Regular physical activity, adequate sleep, and mindfulness-based techniques may help moderate the stress response and, by extension, reduce the severity of shedding episodes. Whilst these measures will not halt the natural hair cycle, they can meaningfully reduce the overall hair loss burden during vulnerable periods.

Treatment Options Available Through the NHS and Privately

Seasonal shedding rarely requires pharmacological treatment, but persistent or distressing hair loss may be managed with topical minoxidil (OTC, MHRA-licensed) or, under clinical supervision, oral minoxidil or finasteride for androgenetic alopecia.

Because seasonal shedding is self-limiting, it does not typically warrant pharmacological treatment. However, when hair loss is persistent, progressive, or causing significant psychological distress, a range of evidence-based options are available through the NHS and via private dermatology services.

NHS-funded investigations and treatments are guided by NICE CKS and British Association of Dermatologists (BAD) recommendations. A GP can arrange blood tests to exclude treatable underlying causes. If hypothyroidism is identified, levothyroxine replacement will often improve hair loss as a secondary benefit. Iron deficiency is treated with oral ferrous sulphate supplementation under clinical supervision.

For confirmed androgenetic alopecia, topical minoxidil (available as a solution or foam) is MHRA-licensed for both male and female pattern hair loss and is the most widely used first-line treatment. It is generally purchased over the counter (OTC) rather than prescribed on the NHS; routine NHS prescribing in primary care is uncommon. Topical minoxidil prolongs the anagen (growth) phase and increases follicle size, but requires consistent, long-term use to maintain effect — hair loss typically returns if treatment is discontinued. Refer to the MHRA/EMC Summary of Product Characteristics (SmPC) for full prescribing information.

Privately available options include:

• Oral minoxidil: Increasingly used off-label at low doses (typically 0.25–2.5 mg daily) for diffuse hair loss, particularly in women. It is not licensed in the UK for this indication. Key risks include hypertrichosis (unwanted body hair growth), peripheral oedema, tachycardia, and postural hypotension. It should only be initiated and monitored by a clinician, with appropriate cardiovascular assessment beforehand. Drug interactions should be reviewed with a prescriber.

• Finasteride 1 mg: A 5-alpha reductase inhibitor licensed by the MHRA for male androgenetic alopecia. It is not recommended in women of childbearing potential due to teratogenic risk; women who are pregnant or may become pregnant must not handle crushed or broken tablets. The MHRA has issued a Drug Safety Update advising that finasteride is associated with a risk of depression, suicidal ideation, and sexual dysfunction (including effects that may persist after stopping treatment). Patients should be counselled about these risks before starting treatment; if depression or suicidal thoughts occur, treatment should be stopped and medical advice sought promptly. A patient alert card is provided with some finasteride products.

• Dutasteride: Another 5-alpha reductase inhibitor sometimes used for male androgenetic alopecia, but it is not licensed for this indication in the UK (off-label use). The same pregnancy handling precautions and psychiatric/sexual side-effect warnings apply as for finasteride.

• Platelet-rich plasma (PRP) therapy: An emerging treatment involving injection of concentrated growth factors into the scalp. Evidence is promising but not yet sufficient for NHS commissioning.

• Low-level laser therapy (LLLT): Available as clinic-based or home-use devices. Some evidence supports modest benefit in androgenetic alopecia, though data quality varies.

Referral and support: Patients experiencing significant distress related to hair loss should be encouraged to discuss their concerns with their GP. Referral to an NHS dermatologist (or a GP with a specialist interest in dermatology) is appropriate when the diagnosis is uncertain, when first-line treatments have failed, or when psychological impact is substantial. If you choose to consult a trichologist privately, please be aware that trichologists are not medically regulated and are not part of NHS referral pathways; a medical diagnosis should always be sought from a qualified clinician.

Charitable organisations such as Alopecia UK provide valuable peer support and signposting to specialist services.

Reporting side effects: If you experience a suspected side effect from any medicine used for hair loss, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions